Panhypopituitarism

Reading File

Finding Sources

Searching PubMed

panhypopituitarism hypopituitarism

Reading File

Loading Image

I now have everything needed to compose a thorough answer. Here is a complete, authoritative review of panhypopituitarism:

Panhypopituitarism

Panhypopituitarism refers to a defect in all pituitary hormone lines - a complete failure of anterior pituitary secretion resulting in deficiency of GH, ACTH, TSH, LH, FSH, and prolactin. Posterior pituitary (ADH, oxytocin) may or may not be affected depending on the cause. - Goldman-Cecil Medicine, p. 2399

Hypothalamic-Pituitary Anatomy (Relevant to Pathophysiology)

Hypothalamic-pituitary vascular and hormonal relationships

The anterior pituitary receives hypothalamic releasing hormones (GHRH, CRH, TRH, GnRH) via the hypophyseal portal system at the median eminence. The posterior pituitary receives vasopressin and oxytocin axons directly. Hypofunction occurs when approximately 75% of the parenchyma is lost or absent. - Robbins Pathologic Basis of Disease

Etiology and Classification

Congenital / Developmental Causes

Category	Examples
Embryopathic	Anencephaly, pituitary aplasia, septo-optic dysplasia (midline cleft defects)
Genetic - transcription factors	PROP1 mutation (most common): GH + PRL + TSH + gonadotropin deficiency; PIT1/POU1F1: GH + PRL + TSH; TPIT: ACTH deficiency; NR5A1/SF1: gonadotrope + adrenal/gonadal
Genetic - signaling	HESX1, SOX2, SOX3, LHX3, LHX4, OTX, GLI2, PAX6, BMP4, FGFR1, CHD7, and >50 others
Isolated GnRH deficiency	Kallmann syndrome (KAL gene - GnRH deficiency + anosmia)

Over 80% of PROP1 mutation patients have growth retardation; by adulthood, all are TSH/gonadotropin deficient; a minority later develop ACTH deficiency. - Harrison's 22e, p. 1647

Acquired Causes

Tumors / Mass Lesions

Pituitary macroadenomas (most common acquired cause) - compress normal cells within the bony sella
Craniopharyngiomas, meningiomas, gliomas, dysgerminomas
Metastatic tumors (breast, lung, colon carcinoma), Rathke cleft cysts, hypothalamic hamartomas, lymphoma/leukemia

Vascular

Sheehan syndrome (postpartum necrosis): most common cause of ischemic necrosis - the anterior pituitary doubles in size during pregnancy without proportional increase in blood supply; postpartum hemorrhage/shock precipitates infarction. The posterior pituitary (direct arterial supply) is typically spared.
Pituitary apoplexy: sudden hemorrhage into a pituitary gland or adenoma - presents with severe headache, diplopia, acute hypopituitarism; ACTH loss causes acute adrenal insufficiency, hypotension, cardiovascular collapse - a neurosurgical emergency
Subarachnoid hemorrhage, sickle cell disease, arteritis, snake bite venom, internal carotid aneurysm

Traumatic

TBI, surgical excision, subarachnoid hemorrhage, contact sports, explosive injury - 25-40% of these patients develop hypothalamic or pituitary dysfunction on long-term follow-up

Radiation

Up to 2/3 of patients develop hormone insufficiency after ~50 Gy to skull base; occurs over 5-15 years; usually reflects hypothalamic damage rather than direct pituitary destruction. Order of loss: GH > gonadotropins > TSH > ACTH

Infiltrative / Inflammatory

Sarcoidosis, histiocytosis X, hemochromatosis, amyloidosis, tuberculosis, lymphocytic hypophysitis, granulomatous hypophysitis
Immune checkpoint inhibitors (CTLA-4 inhibitors, PD-1/PD-L1 inhibitors) - autoimmune hypophysitis

Empty Sella Syndrome

Primary: defect in diaphragma sellae allows CSF herniation, compressing pituitary
Secondary: mass enlarges sella, then is removed or infarcted
Goldman-Cecil Medicine, Table 205-1; Robbins Pathologic Basis of Disease, pp. 821-847; Harrison's 22e, pp. 1638-1793

Sequence of Hormone Loss

A key clinical pattern: trophic hormone failure follows a predictable sequence as pituitary compression/destruction worsens:

GH → FSH → LH → TSH → ACTH

During childhood, growth retardation is usually the first sign; in adults, hypogonadism (secondary amenorrhea or male impotence) is the earliest symptom. - Harrison's 22e, p. 1760

Clinical Features by Hormone Deficiency

Hormone Lost	Adult Manifestations	Childhood Manifestations
GH	Decreased lean mass, increased fat, fatigue, dyslipidemia	Growth failure, short stature (pituitary dwarfism)
FSH/LH (Gonadotropins)	Females: amenorrhea, infertility, loss of secondary sex characteristics; Males: impotence, loss of libido, loss of pubic/axillary hair	Failure to enter puberty; no adult sexual development
TSH	Features of secondary hypothyroidism: lethargy, weight gain, cold intolerance	Growth retardation
ACTH	Secondary adrenal insufficiency: hypotension, fatigue, hypoglycemia, hyponatremia (no hyperkalemia - aldosterone preserved)
Prolactin	Failure of postpartum lactation

The overall picture of adult panhypopituitarism is a lethargic patient who is gaining weight (due to loss of thyroid, GH, ACTH, and adrenocortical hormones) with lost sexual function. - Guyton & Hall Medical Physiology, p. 925

Pituitary dwarfism (childhood panhypopituitarism): proportionate short stature; at age 10 may have the body of a 4-5 year old; at age 20, the body of a 7-10 year old. In 1/3 of dwarfism cases, only GH is deficient - these patients do mature sexually. - Guyton & Hall, p. 925

Sheehan syndrome: classic presentation is failure to lactate postpartum, followed by loss of pubic/axillary hair, then amenorrhea, hypothyroid features, and eventually adrenal insufficiency.

Diagnosis

Biochemical Evaluation

Hormone	Test	Normal Response
GH	Insulin tolerance test (ITT): insulin 0.05-0.15 U/kg IV	If glucose <40 mg/dL, GH should rise to >5 µg/L
	Arginine-GHRH test	GH >4.1 µg/L
	Glucagon stimulation test	GH >3 µg/L
ACTH/Cortisol	ITT (gold standard)	Cortisol should rise by >7 µg/dL or reach >20 µg/dL
	CRH test	ACTH increases 2-4 fold; cortisol reaches 20-25 µg/dL
	Short Synacthen (ACTH₂₄) test	Cortisol >18-20 µg/dL at 30-60 min
TSH	Basal TSH + free T4	Low/normal TSH with low free T4 = secondary hypothyroidism
LH/FSH	Basal levels + sex steroids	Low gonadotropins with low testosterone/estradiol
Prolactin	Basal serum PRL	Low in panhypopituitarism (contrast with hyperprolactinemia from stalk compression)

Goldman-Cecil Medicine, Table 205-2, p. 2400

Basal hormone levels are often insufficient alone; dynamic stimulation testing is required for GH and ACTH.

Imaging

MRI of the pituitary is the preferred modality - evaluates for mass lesions, empty sella, pituitary size, stalk, and hypothalamic involvement.

Treatment

Two-pronged approach: (1) replace deficient hormones, (2) address the underlying cause. - Goldman-Cecil Medicine, p. 2400

Deficiency	Replacement
ACTH / Adrenal	Hydrocortisone (15-20 mg/day in divided doses, or ~10 mg morning + 5 mg afternoon); stress dosing essential. This is the most life-threatening deficiency - treat first.
TSH / Thyroid	Levothyroxine; do NOT replace without first correcting cortisol deficiency (risk of adrenal crisis)
LH/FSH / Gonadal	Males: testosterone (IM, transdermal, or gel); Females: estrogen ± progesterone; if fertility desired, gonadotropin injections (FSH + LH or hMG)
GH	Recombinant human GH (rhGH) subcutaneous injection; can cure GH-deficient dwarfism if started early
ADH (if posterior pituitary involved)	Desmopressin (DDAVP) intranasal or oral
Prolactin	No replacement needed in most cases

Critical teaching point: Always replace glucocorticoids before thyroid hormone - thyroid replacement in the setting of adrenal insufficiency can precipitate a life-threatening adrenal crisis by increasing cortisol metabolism.

Special Situations

Pituitary apoplexy: neurosurgical emergency; urgent glucocorticoid replacement + consideration of surgical decompression
Checkpoint inhibitor-induced hypophysitis: a growing cause in oncology patients on CTLA-4 or PD-1/PD-L1 inhibitors; often presents with headache and pituitary enlargement on MRI
Pregnancy: women with hypopituitarism can achieve pregnancy with gonadotropin therapy but require careful hormonal monitoring throughout

Recent Evidence (PubMed, 2024-2026)

A systematic review on pituitary stalk sacrifice during craniopharyngioma surgery (Bobeff et al., 2025) confirmed that pituitary stalk preservation significantly reduces postoperative endocrine dysfunction, though recurrence rates must be balanced.
A meta-analysis on stereotactic radiosurgery for non-functioning pituitary adenomas (De Nigris Vasconcellos et al., 2024) found significant rates of post-SRS hypopituitarism, reinforcing long-term endocrine follow-up after radiation.
A 2025 report with systematic review identified biallelic POMC mutations as a rare cause of combined pituitary hormonal deficiency associated with severe obesity.

Sources: Guyton & Hall Medical Physiology, p. 924-925 | Robbins Pathologic Basis of Disease, pp. 821-859 | Harrison's Principles of Internal Medicine 22e, pp. 1638-1793 | Goldman-Cecil Medicine, pp. 2398-2401

Wysolone

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have excellent content from multiple authoritative sources. Here is the complete profile of Wysolone (prednisolone):

Wysolone (Prednisolone)

Brand name: Wysolone (Sun Pharma, India) Generic name: Prednisolone Class: Synthetic glucocorticoid (corticosteroid) Available strengths: 5 mg, 10 mg, 20 mg, 40 mg tablets

What Is It?

Prednisolone is the active form of prednisone. Unlike prednisone, which requires hepatic conversion to its active metabolite, prednisolone is directly active - making it the preferred choice in patients with liver disease. It is a synthetic analog of cortisol (hydrocortisone) with predominantly glucocorticoid activity and minimal mineralocorticoid effect.

Mechanism of Action

Corticosteroids exert a pluripotent anti-inflammatory effect via inhibition of inflammatory mediator gene transcription. Specifically:

Binds to cytosolic glucocorticoid receptors (GR), causing receptor-ligand complex to translocate to the nucleus
Transrepression: Blocks transcription factors NF-κB and AP-1, reducing synthesis of pro-inflammatory cytokines (IL-1, IL-2, IL-6, TNF-α), COX-2, and phospholipase A2
Transactivation: Upregulates anti-inflammatory genes (lipocortin/annexin-1, which inhibits phospholipase A2 and arachidonic acid cascade)
Reduces vascular permeability, inhibits leukocyte migration, and suppresses T-cell and B-cell function at higher doses
Washington Manual of Medical Therapeutics, p. 975; Goodman & Gilman's Pharmacological Basis of Therapeutics

Relative Anti-inflammatory Potency (Comparison Table)

Drug	Relative Anti-inflammatory Potency	Mineralocorticoid Activity	Biological Half-life
Cortisone	0.8	++	8-12 h
Hydrocortisone	1 (reference)	++	8-12 h
Prednisolone	4	+	12-36 h
Prednisone	4	+	12-36 h
Methylprednisolone	5	Minimal	12-36 h
Dexamethasone	25	None	36-54 h

Prednisolone has ~4x the anti-inflammatory potency of hydrocortisone with significantly less mineralocorticoid effect (no significant sodium/water retention at usual doses). - Washington Manual, p. 975

Therapeutic Uses

Wysolone/prednisolone is used across a very wide spectrum:

Rheumatological / Autoimmune

Rheumatoid arthritis (low-dose, bridging therapy)
Systemic lupus erythematosus (SLE)
Polymyalgia rheumatica, vasculitides
Inflammatory myopathies (dermatomyositis, polymyositis)
Sarcoidosis

Respiratory

Acute severe asthma (systemic burst)
COPD exacerbations
Interstitial lung disease
Croup (single dose)

Dermatological

Severe eczema/atopic dermatitis
Pemphigus, pemphigoid
Severe urticaria/angioedema

Gastroenterological

Inflammatory bowel disease (Crohn's disease, ulcerative colitis) - induction of remission
Autoimmune hepatitis (combination with azathioprine)

Haematological / Oncological

Immune thrombocytopenic purpura (ITP)
Autoimmune hemolytic anemia
Lymphoma/leukemia regimens (e.g., CHOP, MOPP)
Nephrotic syndrome (minimal change disease - first-line)

Neurological

Bell's palsy
Multiple sclerosis relapses
Cerebral edema (dexamethasone preferred but prednisolone used)

Endocrine / Replacement

Congenital adrenal hyperplasia (CAH)
Addison's disease (less preferred than hydrocortisone)

Transplant

Part of immunosuppression regimens post-organ transplant
Goodman & Gilman's: "Across the spectrum of inflammatory disease"

Dosing

Dosing is highly disease-dependent:

Indication	Typical Dose
Anti-inflammatory (low dose)	5-10 mg/day
Moderate inflammatory disease	20-40 mg/day
High dose (nephrotic, severe asthma)	1 mg/kg/day (up to 60-80 mg/day)
Pulse / very high dose	500 mg-1 g IV methylprednisolone preferred
Tapering	Gradual reduction once disease controlled

Key principle: Use the minimum effective dose for the shortest duration possible. - Washington Manual, p. 975

Prednisone vs. prednisolone equivalence: They are equipotent (4x hydrocortisone). 5 mg prednisolone = 5 mg prednisone = 20 mg hydrocortisone = 4 mg methylprednisolone = 0.8 mg dexamethasone.

Adverse Effects

Adverse effects are dose- and duration-dependent. They generally appear at doses >10 mg/day prednisolone equivalent and become significant with prolonged use.

Endocrine / Metabolic

Hyperglycemia / steroid-induced diabetes
Weight gain, central obesity, moon face, buffalo hump (iatrogenic Cushing syndrome)
HPA axis suppression: adrenal suppression can be assumed in patients receiving >20 mg/day for >3 weeks; abrupt discontinuation risks adrenal crisis
Osteoporosis: start calcium (1-1.5 g/day) + vitamin D (1000 IU/day) from initiation; bisphosphonates for prophylaxis in long-term use
Growth retardation in children

Cardiovascular

Dyslipidemia (raised LDL, lowered HDL)
Hypertension (sodium retention, increased cardiac output)
Increased risk of atherosclerosis with long-term use

Ophthalmological

Posterior subcapsular cataracts (dose and duration related)
Glaucoma (raised intraocular pressure)

Immunological

Reduced resistance to infections - minor infections can become systemic; quiescent infections (TB, fungi) reactivated
Infection signs may be partially masked
Consider PCP (Pneumocystis jirovecii) prophylaxis (cotrimoxazole) for patients on ≥20 mg/day for >1 month
Reactivation of latent TB - screen with TST/IGRA before starting

Psychiatric

Insomnia (especially early in therapy)
Euphoria, emotional lability
Severe depression or steroid psychosis (at high doses)

Musculoskeletal

Proximal myopathy (painless weakness of proximal muscles; normal CK/EMG; resolves on stopping)
Avascular necrosis (osteonecrosis) of femoral head, humeral head, tibial plateau - a serious complication

Dermatological

Acne, skin atrophy, striae, purpura, easy bruising, poor wound healing

Gastrointestinal

GI irritation, peptic ulceration (risk increased with NSAIDs co-prescription)
Use PPI prophylaxis if also on NSAIDs or high dose
Goodman & Gilman's: "With high-dose/long-term therapy: psychosis, increased susceptibility to infection, osteoporosis, osteonecrosis, myopathy, HPA axis suppression"
Washington Manual of Medical Therapeutics, pp. 975-976
Yamada's Gastroenterology: "Up to 80% of patients suffer from prednisone/prednisolone-specific side effects"

Key Precautions and Contraindications

Situation	Consideration
Active infections	Caution - may mask signs; treat infection alongside steroids when life-threatening inflammation present
Diabetes mellitus	Monitor blood glucose closely; may need insulin adjustment
Hypertension	Monitor BP; sodium restriction
Peptic ulcer disease	Add PPI; use lowest dose
Osteoporosis	Prophylaxis with calcium/vit D/bisphosphonates mandatory
Latent TB	Screen and give isoniazid prophylaxis
Liver disease	Prednisolone preferred over prednisone (prednisone requires hepatic conversion)
Pregnancy	Category C; used when benefits outweigh risks; minimal placental transfer compared to dexamethasone/betamethasone
Abrupt cessation	Never stop abruptly after >3 weeks - risk of adrenal crisis; taper gradually

Tapering

After prolonged use, the dose must be tapered gradually to:

Allow the HPA axis to recover (prevent adrenal crisis)
Prevent flare of the underlying disease

A typical taper reduces the dose by ~10-20% every 1-2 weeks, slowing as the dose approaches physiological levels (5-7.5 mg/day equivalent).

Stress Dosing

Patients on long-term prednisolone who undergo surgery, major illness, or severe stress require "stress-dose" glucocorticoids (equivalent to hydrocortisone 50-100 mg IV q6-8h) because their HPA axis cannot mount an adequate cortisol response independently.

Drug Interactions

Interacting Drug	Effect
NSAIDs	Additive GI ulceration risk
Antidiabetic drugs	Reduced efficacy (steroid-induced hyperglycemia)
Antihypertensives	Reduced efficacy
Vaccines (live)	Avoid live vaccines (MMR, varicella) in patients on immunosuppressive doses
CYP3A4 inducers (rifampicin, phenytoin)	Reduced prednisolone levels
CYP3A4 inhibitors (ketoconazole)	Increased prednisolone levels
Warfarin	Variable interaction; monitor INR

Sources: Washington Manual of Medical Therapeutics, pp. 975-976 | Goodman & Gilman's Pharmacological Basis of Therapeutics | Sleisenger & Fordtran's GI and Liver Disease | Yamada's Textbook of Gastroenterology

This is a shared conversation. Sign in to Orris to start your own chat.